{"classes":[{"categories":[{"measurements":[{"comment":"Confidence Interval was not estimable","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"7.1"},{"comment":"Upper Confidence Interval was not estimable","groupId":"OG001","lowerLimit":"6.3","upperLimit":"NA","value":"16.4"},{"comment":"No participants experienced CR or PR for this cohort","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants experienced CR or PR for this cohort","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"TTR is defined as the time from date of the first dose to date of first documented response (CR or PR)","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive","id":"OG000","title":"Anaplastic Large Cell Lymphoma (ALCL)"},{"description":"Patients diagnosed with IMT with a confirmed translocation involving the ALK gene","id":"OG001","title":"Inflammatory Myofibroblastic Tumor (IMT)"},{"description":"Patients with GBM with a translocation involving the ALK gene","id":"OG002","title":"Glioblastoma (GBM)"},{"description":"Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).","id":"OG003","title":"Any Other ALK-positive Tumor"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline, every 8 weeks until disease progression or end of treatment, whichever came first, assessed up to approximately 84 weeks","title":"Time to Response (TTR) Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"weeks"}